Studies blood and bone marrow samples from people with myeloma
Collects blood and bone marrow samples from adults with myeloma to test new drugs.
Key facts
- Who runs it
- Institute of Cancer Research, United Kingdom
- Where
- Sutton, United KingdomSee the site
- Trial code
- Registry title
- Myeloma Novel Drug Discovery Ver 1.2
- Status
- Recruiting
- People taking part
- 250 people, planned
- Started
- 22 Jul 2020
- Expected to end
- 28 Feb 2035
- Type of study
- Observational
- Treatments tested
- Observational study - sample collection only.
- Record updated
- 3 August 2023
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with myeloma or a related plasma cell disorder, or a suspected one, who are having a blood or bone marrow sample taken and agree to give one extra sample for lab research.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Myeloma or a related plasma cell disorder, or a suspected diagnosis. People can be before, during or after anti-myeloma treatment.
Main reasons for not taking part
- Cannot give consent
- Known active infectious disease (for example HIV, Hepatitis B/C, COVID) that is a risk to using the sample in the laboratory
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Participants who have a diagnosis, or suspected diagnosis, of myeloma or related plasma cell disorder
- Participants who are undergoing a peripheral blood or bone marrow aspirate sampling for diagnostic, staging or follow-up purposes, before, whilst or after receiving anti-myeloma treatment
- Participants aged 18 years of age or above
- Participants willing to consent to an additional sample being taken at the time of their peripheral blood or bone marrow aspirate sampling
Who cannot take part
- Participants with known active infectious diseases (e.g. HIV, Hepatitis B/C, COVID) that pose a risk to the use of the sample in the laboratory
- Participants unable to provide consent
Where in United Kingdom
- The Royal Marsden NHS Foundation TrustSutton, United KingdomContact: Chloe BurrowsTaking people
About the trial
What the trial wants to find out
Myeloma is a bone marrow cancer with over 5000 patients diagnosed in the UK each year. Researchers are committed to improving understanding of myeloma and developing more effective treatments with fewer side effects in order to improve patient outcomes. In order to do this, researchers are collecting samples of blood and bone marrow to test the activity of potential new treatments in the laboratory and to understand what may be the cause of some treatments not working.
The group in the trial
- Participants with a diagnosis, or suspected diagnosis, of myeloma or related plasma cell disorder
Participants who are undergoing peripheral blood or bone marrow aspirate sampling for diagnostic, staging or follow-up purposes, before, whilst or after receiving anti-myeloma treatment will be approached to collect additional samples for research.
Treatment: Observational study - sample collection only.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Investigation of the Activity of Novel Compounds for the Treatment of Myeloma and Mechanisms of Drug Resistance to Current Therapies
- Plain-language title
- Studies blood and bone marrow samples from people with myelomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 3 August 2023